CEFUZONAM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H15N7O5S4
Molecular Weight	513.594
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC3=CN=NS3)=C(N2C1=O)C(O)=O)C4=CSC(N)=N4

InChI

InChIKey=CXHKZHZLDMQGFF-ZSDSSEDPSA-N

InChI=1S/C16H15N7O5S4/c1-28-21-9(7-5-31-16(17)19-7)12(24)20-10-13(25)23-11(15(26)27)6(4-30-14(10)23)3-29-8-2-18-22-32-8/h2,5,10,14H,3-4H2,1H3,(H2,17,19)(H,20,24)(H,26,27)/b21-9-/t10-,14-/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3613097
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/3322588

Cefuzoname (CZON, L-105) is a second-generation cephalosporin antibiotic, has broad spectrum on Gram-positive or -negative bacteria and may also be effective against Staphylococcus aureus against which third generation cephalosporins are largely ineffective.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Klebsiella pneumoniae growth 4 Target ID: Klebsiella pneumoniae growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/3613094	Inhibitor 8504
Escherichia coli growth 23 Target ID: Escherichia coli growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/3613094	Inhibitor 8504
Peptidoglycan biosynthesis 20 Target ID: map00550 Sources: http://www.kegg.jp/dbget-bin/www_bget?dr:D03432	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Chronic complicated urinary tract infection 2 Sources: http://www.ncbi.nlm.nih.gov/pubmed/3806950	Curative	Preclinical	Unknown Approved Use Unknown
Bronchopneumonia 4 Sources: http://www.ncbi.nlm.nih.gov/pubmed/3613086	Curative	Preclinical	Unknown Approved Use Unknown
Acute appendicitis 2 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1960860	Curative	Preclinical	Unknown Approved Use Unknown
Lung abscess 2 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2071958	Curative	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Clinical studies on cefuzonam for acute peritonitis due to perforated appendicitis. Tissue concentration and clinical efficacy].	1991-09	1960860
Bone cement not weakened by cefuzonam powder.	1991-06	2042464
[Clinical evaluation of cefuzonam (CZON) for bacterial pneumonia and lung abscess: comparative study with cefotiam (CTM)].	1991-04	2071958
[Fundamental and clinical studies on cefuzoname in the pediatric field].	1987-04	3613094

Patents

Sample Use Guides

In Vivo Use Guide

Cefuzonam in a dose of 1 g was administered by intravenous bolus injection or intravenous drip infusion for 60 minutes.

Route of Administration: Intravenous

In Vitro Use Guide

The MIC80's of cefuzonam against Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Haemophilus influenzae and Citrobacter spp. were less than 0.20 ug/ml.

Name

Type

Language

CEFUZONAM [MI]

Preferred Name

English

CEFUZONAM

Official Name

English

cefuzonam [INN]

Common Name

English

CEFUZONAM [MART.]

Common Name

English

Cefuzonam [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C357